Beigene Ltd (NASDAQ:BGNE) has earned a consensus recommendation of “Buy” from the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $182.08.
A number of analysts have recently weighed in on BGNE shares. Macquarie started coverage on Beigene in a research report on Friday, July 5th. They set an “underperform” rating on the stock. BidaskClub raised Beigene from a “hold” rating to a “buy” rating in a research report on Wednesday, July 31st. Cowen reaffirmed a “buy” rating and set a $170.00 price objective on shares of Beigene in a research report on Friday, May 31st. Morgan Stanley cut their price objective on Beigene from $210.00 to $207.00 and set an “overweight” rating on the stock in a research report on Monday, July 15th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Beigene in a research report on Thursday, June 20th.
NASDAQ:BGNE traded up $1.51 during trading hours on Tuesday, reaching $131.25. 109,315 shares of the stock were exchanged, compared to its average volume of 311,121. The company has a debt-to-equity ratio of 0.14, a current ratio of 7.52 and a quick ratio of 7.47. The stock has a 50-day simple moving average of $127.02. Beigene has a twelve month low of $105.19 and a twelve month high of $182.30. The stock has a market cap of $6.43 billion, a P/E ratio of -10.80 and a beta of 1.03.
In related news, CFO Howard Liang sold 5,876 shares of the stock in a transaction on Thursday, June 27th. The stock was sold at an average price of $9.47, for a total value of $55,645.72. Following the transaction, the chief financial officer now owns 122,317 shares of the company’s stock, valued at $1,158,341.99. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Jane Huang sold 10,130 shares of the stock in a transaction on Monday, July 29th. The shares were sold at an average price of $134.54, for a total value of $1,362,890.20. Following the completion of the transaction, the chief marketing officer now directly owns 328,873 shares in the company, valued at approximately $44,246,573.42. The disclosure for this sale can be found here. Insiders sold 62,916 shares of company stock worth $7,419,025 in the last three months. 13.40% of the stock is currently owned by corporate insiders.
A number of large investors have recently bought and sold shares of the stock. IFM Investors Pty Ltd increased its holdings in Beigene by 6.9% in the second quarter. IFM Investors Pty Ltd now owns 1,949 shares of the company’s stock valued at $242,000 after buying an additional 126 shares during the last quarter. Nissay Asset Management Corp Japan ADV increased its holdings in Beigene by 4.8% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 2,753 shares of the company’s stock valued at $363,000 after buying an additional 127 shares during the last quarter. Comerica Bank increased its holdings in Beigene by 3.5% in the first quarter. Comerica Bank now owns 4,365 shares of the company’s stock valued at $638,000 after buying an additional 146 shares during the last quarter. Quadrant Capital Group LLC increased its holdings in Beigene by 131.8% in the first quarter. Quadrant Capital Group LLC now owns 364 shares of the company’s stock valued at $47,000 after buying an additional 207 shares during the last quarter. Finally, Advisor Group Inc. increased its holdings in Beigene by 301.4% in the fourth quarter. Advisor Group Inc. now owns 285 shares of the company’s stock valued at $40,000 after buying an additional 214 shares during the last quarter.
Beigene Company Profile
BeiGene, Ltd., a commercial-stage biotechnology company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer in the People's Republic of China, the United States, and internationally. Its commercial products include ABRAXANE, a chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.